Module 12: Emerging treatments of dyslipidemia
EAS Academy, EAS, 65173
Translating new approaches to reduce LDL cholesterol into future therapies
EAS Academy, Evan A. Stein, 31569
PCSK9 inhibition, a safe and efficient strategy to lower LDL cholesterol?
EAS Academy, Gilles Lambert, 31567
LDL cholesterol and cardiovascular risk reduction - successes and challenges
EAS Academy, Lale Tokgozoglu, 31565
Pharmacological targets identified by genetic approaches
EAS Academy, Francois Cambien, 31153
Therapeutic options to induce regression of coronary atherosclerosis
EAS Academy, Steven Nissen, 31152
Micro-RNA and epigenetic control of atherogenesis
EAS Academy, Kathryn Moore, 31151
Gut-liver interaction in triglyceride rich lipoprotein metabolism
EAS Academy, Gary Lewis, 31150
Module 15: Lipids, lipoproteins and metabolism (Recommended)
EAS Academy, EAS, 65176
Evaluation Form
EAS Academy, EAS, 259717
Clinical application & safety of plant sterols/stanols
EAS Academy, Henry Ginsberg, 31560
Normalising Dyslipidemia and Reversing Atherosclerosis in Cardiometabolic Disease: Insights from Statin Pharmacotherapy
EAS Academy, John Chapman, 31556
Basic science of plant sterols/stanols
EAS Academy, Jogchum Plat, 31559
Normalising Dyslipidemia and Reversing Atherosclerosis in Cardiometabolic Disease: Insights from Statin Pharmacotherapy Introduction
EAS Academy, Yasushi Saito, 31555
Emerging LDL-C-lowering therapies - Targeting clearance
EAS Academy, Michel Farnier, 31553
New and emerging LDL-C-lowering therapies - Targeting production
EAS Academy, Erik Stroes, 31552
The spectrum of difficult-to-treat hypercholesterolemic patients
EAS Academy, Christie M. Ballantyne, 31551
Prevention and treatment of plaque thrombogenicity
EAS Academy, Gilles Montalescot, 31149
Advances in visualizing the unstable plaque
EAS Academy, Filippo Crea, 31148
New insights into the role of hemodynamics in plaque instability
EAS Academy, Yiannis Chatzizisis, 31147
Biomarkers of plaque of instability
EAS Academy, Jean-Baptiste Michel, 31146
THE ANITSCHKOW LECTURE
EAS Academy, Peter Libby, 31159
EAS/ESC recommendations for the management of patients with HoFH
EAS Academy, Eric Bruckert, 31545
What are we able to achieve for our patients today?
EAS Academy, Raul D. Santos, 31544
Current treatment of dyslipidaemia in patients with the metabolic syndrome
EAS Academy, Borge Nordestgaard, 31537
Risk of diabetes development during statin treatment
EAS Academy, Naveed Sattar, 31535
Hypercholesterolemia - What can we do for high-risk patients?
EAS Academy, Kees Hovingh, 31540
Lipid metabolism and cardiovascular disease in diabetes
EAS Academy, Marja-Riitta Taskinen, 31533
Module 2: Arterial wall in atherosclerosis
EAS Academy, EAS, 65162
Module 4: Basics on lipids as risk factors
EAS Academy, EAS, 65164
Module 16: Therapy (Recommended)
EAS Academy, EAS, 65177
Future treatments
EAS Academy, Alberico L. Catapano, 27925
Pathophysiology of Atherosclerosis
EAS Academy, Goran Hansson, 27924
Familial hypercholesterolemia in clinical practice
EAS Academy, Kees Hovingh, 27922
Latest updates on Familial Hypercholesterolaemia
EAS Academy, EAS, 113064
Module 8: Familial dyslipidemias
EAS Academy, EAS, 65168
Diabetes, metabolic syndrome
EAS Academy, Marja-Riitta Taskinen, 27921
Imaging to detect atherosclerosis and in risk assessment
EAS Academy, Goran Bergstrom, 27920
Module 3: Risk assessment with risk algorithms and guidelines
EAS Academy, Olov Wiklund, 99032
Epidemiology. Development of cardiovascular disease in different populations
EAS Academy, Annika Rosengren, 27918
Module 2: Epidemiology. Development of cardiovascular disease in different populations
EAS Academy, Annika Rosengren, 99031
Basics in Lipoprotein Metabolism
EAS Academy, Jan Borén, 27917
Module 6: Basics in Lipoprotein Metabolism
EAS Academy, Jan Borén, 99035
Module 1: Epidemiology of ASVD
EAS Academy, Annika Rosengren, 65161
Module 3: Risk assessment and guidelines
EAS Academy, EAS, 65163
Module 5: Risk factors: Lipoprotein(a) and triglycerides
EAS Academy, EAS, 65165
Personal Information
EAS Academy, Annika Rosengren, 98395
Module 6: Lipids, lipoproteins and metabolism
EAS Academy, EAS, 65166
Familial hypercholesterolemia: can we do better job? Molecular Genetics: is the screening of lipid disorders useful in clinical practice?
EAS Academy, Sebastiano Calandra, 25428
Imaging of arteries: does it help to improve risk evaluation?
EAS Academy, Lale Tokgozoglu, 25427
Module 9: Imaging and Biomarkers in diagnosis of atherosclerosis
EAS Academy, EAS, 65169
New Therapeutic Approaches in Lipidology
EAS Academy, Alberico L. Catapano, 25426
Update on new EAS/ESC Joint European Guidelines for the Prevention and Treatment of Dyslipidemia
EAS Academy, Alberico L. Catapano, 25425
Update on HDL biology: structure, metabolism and function in health and disease
EAS Academy, Petri Kovanen, 25423
Atherosclerosis: update on the pathophysiology: role of LDL
EAS Academy, Petri Kovanen, 25422
Module 7: Atherosclerosis: update on the pathophysiology: role of LDL
EAS Academy, Petri Kovanen, 99036
ECONOMIC ISSUES IN CARDIOVASCULAR DISEASE: WHAT ARE THE COSTS OF PREVENTION?
EAS Academy, Giuseppe Mancia, 20874
NEW PERSPECTIVES IN HYPOLIPIDEMIC TREATMENT
EAS Academy, John J.P. Kastelein, 20875
LIFESTYLE AND NUTRITIONAL STRATEGIES IN PREVENTING CARDIOVASCULAR DISEASE
EAS Academy, Aila Rissanen, 20873
GENERAL TRENDS OF CARDIOVASCULAR DISEASE IN EUROPE AND RISK FACTORS IN SPECIAL POPULATIONS
EAS Academy, Borge Nordestgaard, 20872
Module 13: Lifestyle and nutrition in cardiovascular prevention
EAS Academy, EAS, 65174
Module 14: Epidemiology of ASVD (Recommended)
EAS Academy, Borge Nordestgaard, 65175
Pitavastatin: addressing challenges: JAPAN-ACS and CIRCLE studies
EAS Academy, Hidenori Arai, 21241
Pitavastatin for the management of dyslipidaemia and atherosclerosis
EAS Academy, José-Ramon Gonzalez -Juanatey, 21240
Managing dyslipidaemia complicated with diabetes or high cardiovascular risk: how well are we doing?
EAS Academy, John Betteridge, 21239
CAN WE ENCOURAGE OUR HYPERCHOLESTEROLEMIC PATIENTS TO TAKE PLANT STEROL ENRICHED FOODS?
EAS Academy, Eric Bruckert, 21237
ARE LIPOPROTEIN REMNANTS A REASONABLE TARGET FOR THERAPY?
EAS Academy, Henry Ginsberg, 20869
GENETICS OF ATHEROGENIC DYSLIPIDEMIAS
EAS Academy, Robert Hegele, 20868
NOVEL ANTI-ATHEROGENIC MECHANISMS OF HDL AND ABC TRANSPORTERS
EAS Academy, Alan Tall, 20867
THE MACROPHAGE LIPOPROTEIN INTERACTIONS – FOR GOOD OR FOR BAD
EAS Academy, Miranda van Eck, 20866
New treatment options in patients with severe heterozygous FH: applying antisense technology
EAS Academy, Christie M. Ballantyne, 21236
Metabolic regulation of apoB-containing lipoproteins in severe FH
EAS Academy, Gerald Watts, 21235
Risk factors in severe heterozygous FH
EAS Academy, Eric Bruckert, 21234
Improving patient management – how implementation of the latest guidelines will help
EAS Academy, Lale Tokgozoglu, 21231
Treatment challenges in patients with familial hypercholesterolaemia
EAS Academy, Marcello Arca, 21230
Further reducing cardiovascular risk – what to target?
EAS Academy, Julian Halcox, 21229
UNDERSTANDING THE VULNERABLE PLAQUE – BASIS FOR TREATMENT OPTIONS
EAS Academy, Gerard Pasterkamp, 20863
IMMUNITY IN ATHEROSCLEROSIS
EAS Academy, Goran Hansson, 20862
ENDOTHELIAL FUNCTION AND DYSFUNCTION: THE KEYS TO CORONARY AND PERIPHERAL CIRCULATION
EAS Academy, Ulf Landmesser, 20861
BUILDING A VESSEL WALL: FROM DEVELOPMENTAL BIOLOGY TO PHYSIOLOGICAL AND PATHOLOGICAL REMODELING IN ADULT LIFE
EAS Academy, Mark Majesky, 20860
Intoduction to the Anitschkow lecture
EAS Academy, John Chapman, 20857
A BRIEF HISTORY OF CHOLESTEROL LOWERING
EAS Academy, Terje R Pedersen, 20858
Module 1: A brief history of cholesterol lowering
EAS Academy, Terje R Pedersen, 99030
MODULE 7: PHARMACOLOGICAL TREATMENT OF HYPERCHOLESTEROLEMIA
EAS Academy, Course Faculty, 258490
Module 10: Pharmacological treatment of hypercholesterolemia
EAS Academy, EAS, 65171
Carotid Intima-Media Thickness Measurement
EAS Academy, Alberico L. Catapano, 31176
Assessment of the Brachial Artery Response- Flow-Mediated Dilation
EAS Academy, Alberico L. Catapano, 31177
Comprehensive management of dyslipidemic patients at risk: Should we prescribe antiaggregants?
EAS Academy, Jean-Philippe Collet, 18304
New advances in the role of Lp(a) in atherosclerosis; Therapeutic implications
EAS Academy, Borge Nordestgaard, 18303
Familial hypercholesterolemia: can we do a better job? Molecular Genetics: is the screening of lipid disorders useful in clinical practice?
EAS Academy, Alain Carrié, 18302
Familial hypercholesterolemia: can we do a better job? Molecular Genetics: is the screening of lipid disorders useful in clinical practice?
EAS Academy, Eric Bruckert, 18301
New Therapeutic Approaches in Lipidology
EAS Academy, John Chapman, 18300
Imaging of arteries: does it help to improve risk evaluation?
EAS Academy, Lale Tokgozoglu, 18299
Update on new EAS/ESC Joint European Guidelines for the Prevention and Treatment of Dyslipidemia
EAS Academy, Olov Wiklund, 18298
CV Risk evaluation through Algorithms
EAS Academy, Eric Bruckert, 18297
Update on HDL biology: structure , metabolism and function in health and disease
EAS Academy, John Chapman, 18296
THE NEW EAS/ESC GUIDELINES TO TREAT DYSLIPIDEMIAS
EAS Academy, Alberico L. Catapano, 8236
WHAT IS A HEALTHY DIET, AS DEFINED BY THE CRITERIA OF EVIDENCE-BASED MEDICINE?
EAS Academy, Gabriele Riccardi, 8235
Module 8: What is a healthy diet, as defined by the criteria of evidence-based medicine?
EAS Academy, Gabriele Riccardi, 99038
IMMUNE MODULATION/VACCINATION TO TREAT AND PREVENT ATHEROSCLEROSIS
EAS Academy, Jan Nilsson, 8234

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings